|
|
Enron Mail |
Mark
Do you have any views on the following? ---------------------- Forwarded by Rousseau Anai/ENRON_DEVELOPMENT on 04/19/2000 10:00 AM --------------------------- Anna Gardiner@ECT 04/18/2000 11:39 PM To: David Forster/Corp/Enron@Enron cc: Carol Chew/SIN/ECT@ECT, Mark Dilworth/LON/ECT@ECT, Frank L Davis/HOU/ECT@ECT, Rousseau Anai/ENRON_DEVELOPMENT@ENRON_DEVELOPMENT Subject: Japanese Products on EnronOnline Dave, Carol Chew has raised some concerns with me regarding the offering of EOL Singapore Products in Japan. This is as a result of a conference call that she participated in yesterday with Morten Erik Petterson, Joe Hirl and John Chismar. During the conference call Carol was informed that all GTC's,counterparty approvals,credit limits, tenor limits covering the trading of Singapore products in Japan have been drafted and approved by the US Legal & credit teams. Carol is concerned that if all Singapore products are to be offered in Japan, that all legal and credit approvals for the products and the counterparties trading them should really be made by the relevant UK teams. This is due to the fact that all OTC products currently traded in Singapore are governed by UK law and UK credit regulations. Please could you advise how I should now proceed with this issue. I have spoken to Justin Boyd about this and he has said that he has had no involvement in the approval of products to be traded in Japan. Should I now be asking Justin to review the Singapore products types with the view to them being traded in Japan? Thanks Anna
|